Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus

European Journal of Endocrinology

Volumn 166, Issue 4, 2012, Pages 711-716

  Van Lierop, A H ^a   Hamdy, N A T ^a   Van Der Meer, R W ^a   Jonker, J T ^a   Lamb, H J ^a   Rijzewijk, L J ^b   Diamant, M ^b   Romijn, J A ^a   Smit, J W A ^a   Papapoulos, S E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CREATININE; GLIMEPIRIDE; METFORMIN; PHOSPHATE; PIOGLITAZONE; PROCOLLAGEN TYPE 1 AMINO TERMINAL PROPEPTIDE; PROCOLLAGENASE; SCLEROSTIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; BONE DENSITY; BONE FRAGILITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CIRCULATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OSSIFICATION; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADULT; AGED; BIOLOGICAL MARKERS; BONE AND BONES; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; GENETIC MARKERS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 84859380860     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-1061     Document Type: Article

References (42)

1. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis. Osteoporosis International 2007 18 427-444. (doi:10.1007/s00198-006-0253-4)
2. Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporosis International 2008 19 129-137. (doi:10.1007/s00198-007-0477-y)
3. Betteridge DJ. Thiazolidinediones and fracture risk in patients with type 2 diabetes. Diabetic Medicine 2011 28 759-771. (doi:10.1111/j.1464-5491.2010. 03187.x)
4. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP & Viberti G. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008 31 845-851. (doi:10.2337/dc07-2270)
5. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC & Jilka RL. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002 143 2376-2384. (doi:10.1210/en.143.6.2376)
6. Mabilleau G, Mieczkowska A & Edmonds ME. Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression. Diabetic Medicine 2010 27 925-932. (doi:10.1111/j.1464-5491.2010.03048.x)
7. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P &Lowik CW. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. Journal of Experimental Medicine 2004 199 805-814. (doi:10.1084/jem.20031454)
8. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME & Latham JA. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO Journal 2003 22 6267-6276. (doi:10.1093/emboj/cdg599)
9. Arasu A, Cawthon P, Do T, Arora P, Lui L-Y, Cauley J, Ensrud K &Cummings S. Sclerostin and risk of hip fracture in older women. Journal of Bone and Mineral Research 2011 26 S143. (doi:10.1002/jbmr.167)
10. van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, Bax JJ, de Roos A, Kamp O, Paulus WJ, Heine RJ, Lammertsma AA, Smit JW & Diamant M. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation 2009 119 2069-2077. (doi:10.1161/CIRCULATIONAHA. 108.803916)
11. Rijzewijk LJ, van der Meer RW, Lubberink M, Lamb HJ, Romijn JA, de Roos A, Twisk JW, Heine RJ, Lammertsma AA, Smit JW &Diamant M. Liver fat content in type 2 diabetes: relationship with hepatic perfusion and substrate metabolism. Diabetes 2010 59 2747-2754. (doi:10.2337/db09-1201)
12. van Lierop AH, Witteveen JE, Hamdy NA & Papapoulos SE. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. European Journal of Endocrinology 2010 163 833-837. (doi:10.1530/EJE-10-0699)
13. van Lierop AH, Hamdy NA, Hamersma H, van Bezooijen RL, Power J, Loveridge N & Papapoulos SE. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. Journal of Bone and Mineral Research 2011 26 2804-2811. (doi:10.1002/jbmr.474)
14. Vestergaard P, Rejnmark L & Mosekilde L. Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcified Tissue International 2009 84 45-55. (doi:10.1007/s00223-008- 9195-5)
15. Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H & Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. Journal of Bone and Mineral Research 2009 24 702-709. (doi:10.1359/jbmr.081207)
16. de Paula FJ, Horowitz MC & Rosen CJ. Novel insights into the relationship between diabetes and osteoporosis. Diabetes/Metabolism Research and Reviews 2010 26 622-630. (doi:10.1002/dmrr.1135)
17. Merlotti D, Gennari L, Dotta F, Lauro D & Nuti R. Mechanisms of impaired bone strength in type 1 and 2 diabetes. Nutrition, Metabolism & Cardiovascular Diseases 2010 20 683-690. (doi:10.1016/j.numecd.2010.07.008)
18. Gardner JC, van Bezooijen RL, Mervis B, Hamdy NA, Lowik CW, Hamersma H, Beighton P & Papapoulos SE. Bone mineral density in sclerosteosis; affected individuals and gene carriers. Journal of Clinical Endocrinology and Metabolism 2005 90 6392-6395. (doi:10.1210/jc.2005-1235)
19. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ & Paszty C. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. Journal of Bone and Mineral Research 2008 23 860-869. (doi:10.1359/jbmr.080216)
20. Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G & Fiore CE. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. Journal of Clinical Endocrinology and Metabolism 2010 95 2248-2253. (doi:10.1210/jc.2010-0067)
21. Modder UI, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, Riggs BL & Khosla S. Regulation of circulating sclerostin levels by sex steroids in women and in men. Journal of Bone and Mineral Research 2011 26 27-34. (doi:10.1002/jbmr.128)
22. Thomas DM, Hards DK, Rogers SD, Ng KW & Best JD. Insulin receptor expression in bone. Journal of Bone and Mineral Research 1996 11 1312-1320. (doi:10.1002/jbmr.5650110916)
23. Iglesias P, Arrieta F, Pinera M, Botella-Carretero JI, Balsa JA, Zamarron I, Menacho M, Diez JJ, Munoz T & Vazquez C. Serum concentrations of osteocalcin, procollagen type 1 N-terminal propeptide and beta-CrossLaps in obese subjects with varying degrees of glucose tolerance. Clinical Endocrinology 2011 75 184-188. (doi:10.1111/j.1365-2265.2011.04035.x)
24. Ferron M, Hinoi E, Karsenty G & Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. PNAS 2008 105 5266-5270. (doi:10.1073/pnas.0711119105)
25. Achemlal L, Tellal S, Rkiouak F, Nouijai A, Bezza A, Derouiche el M, Ghafir D & El Maghraoui A. Bone metabolism in male patients with type 2 diabetes. Clinical Rheumatology 2005 24 493-496. (doi:10.1007/s10067-004-1070-9)
26. Garcia-Martin A, Rozas-Moreno P, Reyes-Garcia R, Morales-Santana S, Garcia-Fontana B, Garcia-Salcedo JA & Munoz-Torres M. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 2011 97 234-241. (doi:10.1210/jc.2011- 2186)
27. Isaia GC, Ardissone P, Di SM, Ferrari D, Martina V, Porta M, Tagliabue M & Molinatti GM. Bone metabolism in type 2 diabetes mellitus. Acta Diabetologica 1999 36 35-38. (doi:10.1007/s005920050142)
28. Kindblom JM, Ohlsson C, Ljunggren O, Karlsson MK, Tivesten A, Smith U & Mellstrom D. Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. Journal of Bone and Mineral Research 2009 24 785-791. (doi:10.1359/jbmr.081234)
29. Rosato MT, Schneider SH & Shapses SA. Bone turnover and insulin-like growth factor I levels increase after improved glycemic control in noninsulin-dependent diabetes mellitus. Calcified Tissue International 1998 63 107-111. (doi:10.1007/s002239900498)
30. Zinman B, Haffner SM, Herman WH, Holman RR, Lachin JM, Kravitz BG, Paul G, Jones NP, Aftring RP, Viberti G & Kahn SE. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2010 95 134-142. (doi:10.1210/jc.2009-0572)
31. Capoglu I, Ozkan A, Ozkan B & Umudum Z. Bone turnover markers in patients with type 2 diabetes and their correlation with glycosylated haemoglobin levels. Journal of International Medical Research 2008 36 1392-1398.
32. Okazaki R, Totsuka Y, Hamano K, Ajima M, Miura M, Hirota Y, Hata K, Fukumoto S & Matsumoto T. Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover. Journal of Clinical Endocrinology and Metabolism 1997 82 2915-2920. (doi:10.1210/jc.82.9. 2915)
33. Dormuth CR, Carney G, Carleton B, Bassett K & Wright JM. Thiazolidinediones and fractures in men and women. Archives of Internal Medicine 2009 169 1395-1402. (doi:10.1001/archinternmed.2009.214)
34. Douglas IJ, Evans SJ, Pocock S & Smeeth L. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Medicine 2009 6 e1000154. (doi:10.1371/journal.pmed.1000154)
35. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H & Meier CR. Use of thiazolidinediones and fracture risk. Archives of Internal Medicine 2008 168 820-825. (doi:10.1001/archinte.168.8.820)
36. Bilik D, McEwen LN, Brown MB, Pomeroy NE, Kim C, Asao K, Crosson JC, Duru OK, Ferrara A, Hsiao VC, Karter AJ, Lee PG, Marrero DG, Selby JV, Subramanian U & Herman WH. Thiazolidinediones and fractures: evidence from translating research into action for diabetes. Journal of Clinical Endocrinology and Metabolism 2010 95 4560-4565. (doi:10.1210/jc.2009-2638)
37. Habib ZA, Havstad SL, Wells K, Divine G, Pladevall M &Williams LK. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 2010 95 592-600. (doi:10.1210/jc.2009-1385)
38. Jones SG, Momin SR, Good MW, Shea TK & Patric K. Distal upper and lower limb fractures associated with thiazolidinedione use. American Journal of Managed Care 2009 15 491-496.
39. Solomon DH, Cadarette SM, Choudhry NK, Canning C, Levin R &Sturmer T. A cohort study of thiazolidinediones and fractures in older adults with diabetes. Journal of Clinical Endocrinology and Metabolism 2009 94 2792-2798. (doi:10.1210/jc.2008-2157)
40. Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM &Atkins GJ. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS ONE 2011 6 e25900. (doi:10.1371/journal.pone. 0025900)
41. Marenzana M, Greenslade K, Eddleston A, Okoye R, Marshall D, Moore A & Robinson MK. Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis & Rheumatology 2011 63 2385-2395. (doi:10.1002/art.30385)
42. Padhi D, Jang G, Stouch B, Fang L & Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. Journal of Bone and Mineral Research 2011 26 19-26. (doi:10.1002/jbmr.173)